5-fluoro-4-methyl-3'-[3-(1-methyl-piperidin-4-yl)-propyl]-1H,3'H-[2,5']bibenzoimidazolyl | 1161425-17-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-fluoro-4-methyl-3'-[3-(1-methyl-piperidin-4-yl)-propyl]-1H,3'H-[2,5']bibenzoimidazolyl
• 英文别名: 5-fluoro-4-methyl-2-[3-[3-(1-methylpiperidin-4-yl)propyl]benzimidazol-5-yl]-1H-benzimidazole
• CAS: 1161425-17-7
• 化学式: C₂₄H₂₈FN₅
• 分子量: 405.518
• InChiKey: CGGAVUHQORHWFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
  申请人：Kindrachuk David E.

  公开号：US20090156613A1

  公开（公告）日：2009-06-18

  Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H 4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H 4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H 4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

  描述了具有双环杂环芳基取代的咪唑化合物，这些化合物可用作H4受体调节剂。这种化合物可以用于制备药物组合物，用于调节组脊髓H4受体活性以及治疗由H4受体活性介导的疾病状态、紊乱和症状，例如过敏、哮喘、自身免疫疾病和瘙痒症。
• Heteroaryl Rheb inhibitors and uses thereof
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US11339144B2

  公开（公告）日：2022-05-24

  The present invention provides compounds of general Formula I and I′: compositions thereof, and methods of using same to treat Rheb-mediated disorders.

  本发明提供通式I和I′的化合物： 其组合物，以及用其治疗 Rheb 介导的疾病的方法。
• HETEROARYL RHEB INHIBITORS AND USES THEREOF
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US20210238165A1

  公开（公告）日：2021-08-05

  The present invention provides compounds, compositions thereof, and methods of using the same. Compositions comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of the compound in compositions of this invention is such that it is effective to measurably inhibit Rheb, in a biological sample or in a patient.
• US8084466B2
  申请人：——

  公开号：US8084466B2

  公开（公告）日：2011-12-27
• [EN] BICYCLIC HETEROARYL-SUBSTITUTED IMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR<br/>[FR] IMIDAZOLES BICYCLIQUES SUBSTITUÉ PAR HÉTÉROARYLE CONSTITUANT DES MODULATEURS DU RÉCEPTEUR DE L'HISTAMINE H4
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009079001A1

  公开（公告）日：2009-06-25

  Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.